Founded in 2017, C-Biomex Co., Ltd is a pioneering bio-venture focused on advancing novel theranostics using its exclusive peptide discovery platform technology.
At present, C-Biomex distinguishes itself from traditional peptides through its notable attributes of heightened serum stability, remarkable binding affinity, and selectivity for specific target molecules. These advantages hold considerable promise across a spectrum of therapeutic applications, offering potential advantages in terms of both effectiveness and safety. Currently, we are focusing on peptide radiopharmaceuticals, a field that facilitates the targeted transport of radioactive isotopes to cancerous tissues for dual diagnostic and therapeutic purposes. Supported by robust preclinical data, we are making swift strides in advancing our research and development.
Company Profile
Revolutionizing Radiopharmaceutical Development through the Innovative Peptide Discovery Platform CUS™
Vision & Mission
We will establish fair and sincere partnerships with both domestic and international research institutions and biotech companies. Additionally, we are committed to building trust with shareholders and investors, aiming for mutual growth.
Growing Together
Discovery & Development of innovative theragnostic
With our dedication and relentless research to overcome existing boundaries and create novel theragnostic. Our aim is to lead in technological innovation by pushing the limits and developing new solutions.
Our goal is to evolve into a globally recognized pharmaceutical company focused on new drug development. By doing so, we aim to provide new therapeutic opportunities to patients suffering from rare diseases, ultimately contributing to the enhancement of their quality of life.
Ethical Management
All executives and employees are committed to fulfilling their social responsibilities and fostering a healthy and ethical corporate culture through legal and ethical management practices.
Aiming High
Cha Jun hoe
CEO
- Doctor of Science, Department of Chemistry, POSTECH
- 2007 Researcher of IBN (Singapore)
- 2014 Head of research institute, Engain (CTO)
- CEO of C-Biomex Co., Ltd. from 2017 to the present
As the founder of C-Biomex, Dr. Cha Jun hoe has worked as a poster doctor at RPI and UNC, as well as at Samsung Advanced Institute of Technology (SAIT), Singapore IBN, Japan Sysmex, and as head of ATizen's research institute, he has contributed to the successful development of NK Vue kits. He started research on Peptide Discovery at IBN in Singapore with Dr. Lee Soo-sung, and in 2017, he confirmed CUS™'s marketability, resigned as the head of Engain's research institute, and founded C-Biomex.
After graduating with a master's degree from Seoul National University and a Ph.D. from Purdue University, Dr. Lee song gil build a career as an LG Chem researcher and a Singapore IBN project leader, especially leading research on peptides and carbohydrates at IBN. As the head of C-Biomex's research institute, he leads CUS™'s validation through the discovery of new drug candidates and research and development and pre-clinical tests of all pipelines.
Lee Song-gil
CTO Vice President
- Doctor of Science, Department of Chemistry, Purdue University
- Glycochemical biology/ Post-doctor of CALTECH _Glychemical biology
- Researcher of LG Chem _Development of catalyst and polymer
- Project Leader of IBN (Singapore)
- Bachelor of Science in Food Economics, Korea University
- Celltrion Planning and Coordination Office
- Team Leader of Bio IR, Legochem
- Team Leader of Business Development, Ybiologics
Kim Woo-shik
CFO Managing director
CFO Kim Woo-shik has gained various practical experiences by playing a leading role in planning, business development, investment, and public relations in the growth process of successful bio companies such as Celltrion and LegoChem Biosciences. from Y-Biologics led technology transfer and strategic partnerships with overseas companies such as Pierre Fabre, Dialogics, and Pascal Biosciences, and is currently responsible for business development and investment as CFO of C-Biomex.
Professor Kang Keon-wook obtained a Ph.D. in nuclear medicine from Seoul National University, is currently the head of the Radiology Research Institute of the Seoul National University Medical Research Institute, and is also a member editor of Molecular Imaging and Biology. Based on numerous experiences, consult on various R&D pipelines, including the preparation of IND documents for the preclinical and clinical development of our CBT-001,004 anticancer drugs.
- Doctor of Medicine, Major of Nuclear Medicine, Seoul National University
- Head of Radiation Research Institute at the Medical Research Center of Seoul National University
- Head of the Institute of Translational Medicine at the Medical Life Institute of Seoul National University Hospital
- Vice President of Seoul National University's Institute of Bio-Max
- President of the Nuclear Applied Medicine Promotion Association
- President of the Korean Society of Nuclear Medicine
Professor
Kang Keon-wook
Professor Min-il is a member of Johns Hopkins' research team and has innovative research experience and achievements in the field of anticancer drugs such as CAR-T and Bio-Radiopharmaecutical Therapy. Based on this, promoting the development of better solid cancer treatments through joint research with C- Biomex Co., Ltd. and performing preclinical support for our platform and CBT-001.
- Doctor of Pennsylvania State University Dept Biochemistry, microbiology and molecular biology
- Master of Science in Biology, KAIST
- Professor of Johns Hopkins School of Medicine
Professor
Min-il
Dr. Lee Soo-sung is a nanotechnology expert and former president of the Association of Korean Scientists and Engineers in Singapore, and led research on the optimization of uncertainties, a technical limitation of existing peptide library screening, to establish reliable ultra-efficient screening technology. This screening technology became the foundation of the current peptide drug discovery platform.
- Doctor of Science, Department of Chemistry, Seoul National University
- Post-Doctor of Seoul National University and MIT
- Saehan Institute of Technology
- Researcher of IBN (Singapore)and President of Korean Scientists and Engineers Association in Singapore
Outside Director
Dr. Lee Soo-sung
People
High professionalism and global level competency